PROCEPT BioRobotics (NASDAQ:PRCT) Trading 4.6% Higher
PROCEPT BioRobotics (NASDAQ:PRCT) Trading 4.6% Higher
Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Rating) were up 4.6% on Tuesday . The company traded as high as $42.41 and last traded at $42.21. Approximately 3,049 shares changed hands during trading, a decline of 98% from the average daily volume of 196,265 shares. The stock had previously closed at $40.37.
周二,纳斯达克的股价上涨了4.6%。该公司股价一度高达42.41美元,最新报42.21美元。约3,049股股票在交易中易手,较196,265股的日均成交量下降了98%。该股此前收盘价为40.37美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
A number of research analysts recently weighed in on PRCT shares. KeyCorp began coverage on PROCEPT BioRobotics in a report on Friday, July 15th. They set an "overweight" rating and a $47.00 price objective on the stock. B. Riley assumed coverage on PROCEPT BioRobotics in a research note on Thursday, June 23rd. They set a "buy" rating and a $53.00 price objective for the company. Finally, Wells Fargo & Company started coverage on PROCEPT BioRobotics in a report on Friday. They set an "overweight" rating and a $49.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $43.50.
一些研究分析师最近对PRCT的股票进行了加码。KeyCorp在7月15日星期五的一份报告中开始报道Procept BioRobotics。他们为该股设定了“增持”评级和47.00美元的目标价。B.莱利在6月23日星期四的一份研究报告中对Procept BioRobotics进行了报道。他们为该公司设定了“买入”评级和53.00美元的目标价。最后,富国银行在周五的一份报告中开始报道Procept BioRobotics。他们为该股设定了“增持”评级和49.00美元的目标价。一名投资分析师对该股的评级为持有,七名分析师对该股的评级为买入。根据MarketBeat的数据,该股目前的平均评级为“适度买入”,共识目标价为43.50美元。
PROCEPT BioRobotics Stock Performance
Procept BioRobotics股票表现
The company has a debt-to-equity ratio of 0.22, a quick ratio of 15.27 and a current ratio of 16.01. The firm has a 50 day moving average of $37.74 and a 200-day moving average of $34.83.
该公司的负债权益比率为0.22,速动比率为15.27,流动比率为16.01。该公司的50日移动均线切入位在37.74美元,200日移动均线切入位在34.83美元。
Insider Transactions at PROCEPT BioRobotics
Procept BioRobotics的内幕交易
In related news, Director Thomas M. Krummel sold 20,000 shares of the firm's stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $35.98, for a total value of $719,600.00. Following the completion of the sale, the director now directly owns 82,920 shares in the company, valued at approximately $2,983,461.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 40.80% of the company's stock.
在相关新闻中,董事托马斯·M·克鲁梅尔在一笔日期为6月21日(星期二)的交易中出售了20,000股该公司股票。这些股票的平均价格为35.98美元,总价值为719,600.00美元。出售完成后,董事现在直接拥有该公司82,920股,价值约2,983,461.60美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,这份文件可以在美国证券交易委员会的网站上找到。公司内部人士持有该公司40.80%的股份。
Institutional Inflows and Outflows
机构资金流入和流出
Several hedge funds have recently made changes to their positions in PRCT. Amalgamated Bank acquired a new position in shares of PROCEPT BioRobotics during the first quarter worth $39,000. US Bancorp DE bought a new stake in shares of PROCEPT BioRobotics during the second quarter worth about $37,000. Shell Asset Management Co. bought a new stake in shares of PROCEPT BioRobotics during the second quarter worth about $102,000. MetLife Investment Management LLC bought a new stake in PROCEPT BioRobotics in the 1st quarter worth about $175,000. Finally, JPMorgan Chase & Co. grew its position in PROCEPT BioRobotics by 18.2% in the 1st quarter. JPMorgan Chase & Co. now owns 5,353 shares of the company's stock worth $188,000 after purchasing an additional 825 shares in the last quarter. 76.23% of the stock is owned by institutional investors.
几家对冲基金最近对它们在PRCT的头寸进行了调整。合并银行在第一季度收购了Procept BioRobotics价值3.9万美元的新股票头寸。US Bancorp DE在第二季度购买了Procept BioRobotics价值约3.7万美元的新股。壳牌资产管理公司在第二季度购买了Procept BioRobotics的新股,价值约10.2万美元。大都会人寿投资管理公司在第一季度购买了Procept BioRobotics的新股份,价值约17.5万美元。最后,摩根大通第一季度在Procept BioRobotics的持仓增加了18.2%。摩根大通在上个季度增持了825股,目前持有5,353股该公司股票,价值18.8万美元。76.23%的股份由机构投资者持有。
About PROCEPT BioRobotics
关于Procept BioRobotics
(Get Rating)
(获取评级)
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Procept BioRobotics公司是一家外科机器人公司,开发泌尿外科变革性解决方案。该公司开发、制造和销售AquaBeam机器人系统,这是一种图像引导的外科机器人系统,用于治疗良性前列腺增生症(BPH)的微创泌尿外科手术。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on PROCEPT BioRobotics (PRCT)
- Broadcom Bounces From Institutional Bottom
- Affirm is the Underdog Starring in a Spaghetti Western
- Is Autozone A Buy Before Earnings Are Released?
- Is There Value in Verizon Shares at These Levels?
- MarketBeat Podcast: Stock Market, Bad News is Good News
- 免费获取StockNews.com关于Procept BioRobotics(PRCT)的研究报告
- 博通从机构底部反弹
- 阿奎姆是意大利西部片中的失败者
- AutoZone是在收益发布之前买入的吗?
- 在这些水平上,Verizon的股价有价值吗?
- 市场Beat播客:股市,坏消息就是好消息
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Procept BioRobotics日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Procept BioRobotics和相关公司的最新新闻和分析师评级的每日简要摘要。